Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
For the nine months, revenue was USD 1.02 million compared to USD 3.41 million a year ago. Net loss was USD 36.86 million compared to USD 40.87 million a year ago. Basic loss per share from continuing operations was USD 17 compared to USD 21.6 a year ago.